Affordable Access

Publisher Website

Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents

Authors
Journal
Antiviral Research
0166-3542
Publisher
Elsevier
Publication Date
Volume
71
Issue
1
Identifiers
DOI: 10.1016/j.antiviral.2006.02.007
Keywords
  • Hepatitis B Virus
  • Hepatitis B Virus-S Antigen
  • Hepatitis B Virus-E Antigen
  • Antiviral Activity
  • Oxadiazoles
Disciplines
  • Medicine

Abstract

Abstract Current treatments for chronic hepatitis B virus (HBV) infection include the use of interferon-α and of nucleoside analogs lamivudine, adefovir and entecavir. However, the use of interferon-α has many side effects while that of nucleosidic inhibitors can lead to the emergence of resistant viruses. Hence, new drugs for the treatment of HBV infection are still highly desired. Oxadiazoles have been observed to exhibit antiviral activities against RNA viruses. In this study, a facile synthesis of 2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles is reported. The compounds were then evaluated for their anti-HBV activity. 1-{2-[5-(1-Benzenesulfonyl-propyl)-[1,3,4]oxadiazol-2-yl-sulfanyl]-ethyl}-4-(2-methoxy-phenyl)-piperazine ( 1i) was able to inhibit the expression of the viral antigens, HBsAg and HBeAg in a concentration-dependent manner with no cytotoxic effects and without any effects on the expression of viral transcripts. Concentration- and time-dependent reductions in virion production were also observed. The inhibition of virion production was comparable to that of lamivudine and EC 50 values of 1.63 and 2.96 μM were obtained for compound 1i and lamivudine, respectively. Thus, in addition to the antiviral effects on RNA viruses, oxadiazoles also have anti-HBV activities.

There are no comments yet on this publication. Be the first to share your thoughts.